Trial Profile
A biomarker study to measure proteasome activity in peripheral blood mononuclear cells as an indicator of susceptibility to bortezomib-induced severe neurological adverse events in patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- 04 Dec 2015 New trial record